Argenx Se (ARGX) EBT (2016 - 2026)
Argenx Se's (ARGX) quarterly EBT came in at $541.0 million in Q2 2026, up 88.57% YoY from $286.9 million in Q2 2025, and up 23.52% on a QoQ basis from $438.0 million in Q1 2026.
Argenx Se (ARGX) EBT (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of EBT data on file, last reported at $541.0 million in Q2 2026.
- Quarterly EBT rose 88.57% year-over-year to $541.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 167.47% YoY) and the FY2025 annual result came in at $1.3 billion, up 1401.06% from the prior year.
- EBT climbed to $541.0 million in Q2 2026, from $438.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of $541.0 million in Q2 2026 to a low of -$241.0 million in Q3 2022.
- A 5-year average of $72.6 million and a median of -$28.1 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT sank 886.6% — and 2025, when it soared 2012.28%.
- Tracing ARGX's EBT over 5 years: stood at -$41.2 million in 2022, then sank by 48.35% to -$61.2 million in 2023, then soared by 237.06% to $83.9 million in 2024, then soared by 380.97% to $403.3 million in 2025, then jumped by 34.15% to $541.0 million in 2026.
- The last three EBT figures came in at $541.0 million (Q2 2026), $438.0 million (Q1 2026), and $403.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -294.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 541.00 Mn |
| Mar 31, 2026 | 438.00 Mn |
| Dec 31, 2025 | 403.29 Mn |
| Sep 30, 2025 | 386.05 Mn |
| Jun 30, 2025 | 286.90 Mn |
| Mar 31, 2025 | 202.36 Mn |
| Dec 31, 2024 | 83.85 Mn |
| Sep 30, 2024 | 88.02 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Mar 31, 2024 | -74.35 Mn |
| Dec 31, 2023 | -61.18 Mn |
| Sep 30, 2023 | -83.28 Mn |
| Jun 30, 2023 | -83.86 Mn |
| Mar 31, 2023 | -76.18 Mn |
| Dec 31, 2022 | -41.24 Mn |
| Sep 30, 2022 | -241.02 Mn |
| Jun 30, 2022 | -216.98 Mn |
| Mar 31, 2022 | -230.07 Mn |
| Dec 31, 2021 | 244.88 Mn |
| Sep 30, 2021 | -230.87 Mn |